BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30907681)

  • 1. Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs.
    Gagnon KT; Corey DR
    Nucleic Acid Ther; 2019 Jun; 29(3):116-122. PubMed ID: 30907681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.
    Shen X; Corey DR
    Nucleic Acids Res; 2018 Feb; 46(4):1584-1600. PubMed ID: 29240946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-Engineering RNA Molecules into Therapeutic Agents.
    Egli M; Manoharan M
    Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing disease genes in the laboratory and the clinic.
    Watts JK; Corey DR
    J Pathol; 2012 Jan; 226(2):365-79. PubMed ID: 22069063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and Opportunities for Nucleic Acid Therapeutics.
    Corey DR; Damha MJ; Manoharan M
    Nucleic Acid Ther; 2022 Feb; 32(1):8-13. PubMed ID: 34931905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying accessible sites in RNA: the first step in designing antisense reagents.
    Pan WH; Clawson GA
    Curr Med Chem; 2006; 13(25):3083-103. PubMed ID: 17073649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ENA oligonucleotides as therapeutics.
    Koizumi M
    Curr Opin Mol Ther; 2006 Apr; 8(2):144-9. PubMed ID: 16610767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of antisense oligonucleotide and siRNA-based therapeutics.
    Chi X; Gatti P; Papoian T
    Drug Discov Today; 2017 May; 22(5):823-833. PubMed ID: 28159625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligomeric nucleic acids as antivirals.
    Mescalchin A; Restle T
    Molecules; 2011 Jan; 16(2):1271-96. PubMed ID: 21278679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linear polyethylenimine as a tool for comparative studies of antisense and short double-stranded RNA oligonucleotides.
    Bologna JC; Dorn G; Natt F; Weiler J
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1729-31. PubMed ID: 14565506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the delivery of RNA therapeutics: from concept to clinical reality.
    Kaczmarek JC; Kowalski PS; Anderson DG
    Genome Med; 2017 Jun; 9(1):60. PubMed ID: 28655327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The infinite possibilities of RNA therapeutics.
    Mollocana-Lara EC; Ni M; Agathos SN; Gonzales-Zubiate FA
    J Ind Microbiol Biotechnol; 2021 Dec; 48(9-10):. PubMed ID: 34463324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges.
    Hofman CR; Corey DR
    Cell Chem Biol; 2024 Jan; 31(1):125-138. PubMed ID: 37804835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic oligonucleotides.
    Goodchild J
    Methods Mol Biol; 2011; 764():1-15. PubMed ID: 21748630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense applications for biological control.
    Pan WH; Clawson GA
    J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleic acid therapeutics for hematologic malignancies--theoretical considerations.
    Opalinska JB; Kalota A; Chattopadhyaya J; Damha M; Gewirtz AM
    Ann N Y Acad Sci; 2006 Oct; 1082():124-36. PubMed ID: 17145934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sugar boost: when ribose modifications improve oligonucleotide performance.
    Faria M; Ulrich H
    Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment.
    Yamakawa K; Nakano-Narusawa Y; Hashimoto N; Yokohira M; Matsuda Y
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31470511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of siRNA for therapeutics: efficient synthesis of phosphorothioate RNA utilizing phenylacetyl disulfide (PADS).
    Ravikumar VT; Andrade M; Carty RL; Dan A; Barone S
    Bioorg Med Chem Lett; 2006 May; 16(9):2513-7. PubMed ID: 16481168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical techniques currently used in the pharmaceutical industry for the quality control of RNA-based therapeutics and ongoing developments.
    Demelenne A; Servais AC; Crommen J; Fillet M
    J Chromatogr A; 2021 Aug; 1651():462283. PubMed ID: 34107400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.